Health Catalyst, INC Form 4 insider transactions

Health Catalyst, Inc. CEO Daniel D. Burton sold 55,715 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Health Catalyst's President and COO, Benjamin Albert, is set to receive a grant of 467,000 restricted stock units under the company's 2019 incentive plan.

Health Catalyst's General Counsel, Benjamin Landry, sold 6,175 shares of common stock for $3.353 per share, executed under a pre-arranged 10b5-1 trading plan.

Health Catalyst, Inc. Director Julie Larson-Green was awarded 4,588 restricted stock units, which vested on September 1, 2025.

Health Catalyst Director Duncan Gallagher acquired 4,970 shares of common stock through the vesting of restricted stock units on September 1, 2025.

Health Catalyst's Chief Tech & Product Officer, David Coy Ross, sold 3,360 shares of common stock to cover tax withholding obligations related to RSU vesting.

Health Catalyst's Chief Commercial Officer, Kevin Lee Freeman, disposed of 4,578 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Health Catalyst's Chief Financial Officer, Jason Alger, sold 2,613 shares of common stock to cover tax withholding obligations related to Restricted Stock Unit vesting.

Health Catalyst's Chief Operating Officer, Daniel LeSueur, disposed of 3,663 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Health Catalyst CEO Daniel D. Burton sold 8,335 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Health Catalyst's Chief People Officer, Linda Llewelyn, sold 2,854 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Health Catalyst's General Counsel, Benjamin Landry, sold 3,138 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Health Catalyst, Inc. director Justin Spencer was granted 68,572 restricted stock units as part of the company's non-employee director compensation policy.

Health Catalyst, Inc. Director S. Dawn Smith was granted 36,231 restricted stock units, increasing her beneficial ownership to 101,692 shares.

Health Catalyst, Inc. Director Duncan Gallagher was granted 36,231 restricted stock units, increasing his beneficial ownership to 113,282 shares.

Health Catalyst, Inc. Director Jill Hoggard Green was granted 36,231 restricted stock units, increasing her direct beneficial ownership to 63,937 shares.

Health Catalyst, Inc. Director John A. Kane was granted 36,231 restricted stock units, increasing his beneficial ownership to 170,719 shares, as disclosed in a recent SEC Form 4 filing.

Health Catalyst, Inc. director Julie Larson-Green was granted 36,231 restricted stock units, increasing her beneficial ownership to 111,251 shares.

Benjamin Landry, General Counsel of Health Catalyst, Inc. (HCAT), has sold 6,057 shares of common stock for approximately $23,890, executed under a Rule 10b5-1 trading plan.

Health Catalyst, Inc.'s General Counsel, Benjamin Landry, executed a non-discretionary sale of 3,255 shares of common stock to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Health Catalyst's Chief Operating Officer, Daniel LeSueur, sold 3,802 shares of common stock on June 2, 2025, at $3.6348 per share, solely to satisfy tax withholding obligations related to vested restricted stock units.

Health Catalyst, Inc.'s Chief Commercial Officer, Kevin Lee Freeman, reported the disposition of 4,747 shares of common stock to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Health Catalyst, Inc.'s Chief Financial Officer, Jason Alger, sold 2,712 shares of common stock on June 2, 2025, to satisfy tax withholding obligations related to the vesting of Restricted Stock Units.

Health Catalyst, Inc.'s CEO, Daniel D. Burton, disposed of 8,658 shares of common stock on June 2, 2025, in a non-discretionary 'sell to cover' transaction related to tax withholding from Restricted Stock Unit vesting.

Health Catalyst, Inc.'s Chief People Officer, Linda Llewelyn, disposed of 2,965 shares of common stock on June 2, 2025, solely to cover tax withholding obligations related to the vesting of Restricted Stock Units.

Health Catalyst, Inc. Director Julie Larson-Green reported the vesting of 3,766 restricted stock units, increasing her direct beneficial ownership to 75,020 shares of common stock.

Health Catalyst, Inc. Director Duncan Gallagher acquired 4,080 shares of common stock on June 1, 2025, through the vesting of previously granted restricted stock units.

Daniel LeSueur, Chief Operating Officer of Health Catalyst, Inc., sold 5,209 shares of common stock at a price of $4.0951 per share on May 5, 2025, under a pre-arranged trading plan.

Daniel LeSueur, COO of Health Catalyst, Inc., sold 5,209 shares of common stock at $4.1475 per share on April 3, 2025, under a pre-arranged trading plan.

Benjamin Landry, General Counsel of Health Catalyst, Inc., sold 13,827 shares of common stock at a price of $4.5462 per share on March 6, 2025, under a pre-arranged trading plan.